Heron Therapeutics Inc (HRTX)
2.77
+0.03
(+1.09%)
USD |
NASDAQ |
Jul 03, 16:00
Heron Therapeutics Research and Development Expense (TTM): 46.69M for March 31, 2024
Research and Development Expense (TTM) Chart
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| March 31, 2024 | 46.69M |
| December 31, 2023 | 50.92M |
| September 30, 2023 | 51.02M |
| June 30, 2023 | 63.01M |
| March 31, 2023 | 74.27M |
| December 31, 2022 | 107.51M |
| September 30, 2022 | 125.33M |
| June 30, 2022 | 128.38M |
| March 31, 2022 | 134.78M |
| December 31, 2021 | 130.82M |
| September 30, 2021 | 146.40M |
| June 30, 2021 | 166.98M |
| March 31, 2021 | 175.76M |
| December 31, 2020 | 174.53M |
| September 30, 2020 | 178.36M |
| June 30, 2020 | 163.88M |
| March 31, 2020 | 161.30M |
| December 31, 2019 | 167.38M |
| September 30, 2019 | 159.00M |
| June 30, 2019 | 154.71M |
| March 31, 2019 | 143.44M |
| December 31, 2018 | 140.03M |
| September 30, 2018 | 147.90M |
| June 30, 2018 | 146.32M |
| March 31, 2018 | 144.76M |
| Date | Value |
|---|---|
| December 31, 2017 | 138.58M |
| September 30, 2017 | 120.33M |
| June 30, 2017 | 121.73M |
| March 31, 2017 | 120.42M |
| December 31, 2016 | 103.12M |
| September 30, 2016 | 89.88M |
| June 30, 2016 | 73.88M |
| March 31, 2016 | 62.77M |
| December 31, 2015 | 61.18M |
| September 30, 2015 | 59.12M |
| June 30, 2015 | 59.60M |
| March 31, 2015 | 57.71M |
| December 31, 2014 | 54.83M |
| September 30, 2014 | 48.99M |
| June 30, 2014 | 40.48M |
| March 31, 2014 | 37.00M |
| December 31, 2013 | 32.52M |
| September 30, 2013 | 29.31M |
| June 30, 2013 | 26.72M |
| March 31, 2013 | 18.98M |
| December 31, 2012 | 15.17M |
| September 30, 2012 | 12.88M |
| June 30, 2012 | 12.18M |
| March 31, 2012 | 10.40M |
| December 31, 2011 | 8.207M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
46.69M
Minimum
Mar 2024
178.36M
Maximum
Sep 2020
126.65M
Average
134.78M
Median
Mar 2022
Research and Development Expense (TTM) Benchmarks
| Arcutis Biotherapeutics Inc | 98.37M |
| Marinus Pharmaceuticals Inc | 95.57M |
| Amgen Inc | 5.069B |
| Ionis Pharmaceuticals Inc | 916.03M |
| Ligand Pharmaceuticals Inc | 23.84M |